Muscarinic receptors as a target for drugs treating schizophrenia.
about
A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviorsCentrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in ratsMuscarinic agonists for the treatment of cognition in schizophreniaAllosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.The effect of deficient muscarinic signaling on commonly reported biochemical effects in schizophrenia and convergence with genetic susceptibility loci in explaining symptom dimensions of psychosis.N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement.Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in miceReversal of scopolamine-induced disruption of prepulse inhibition by clozapine in mice.Molecular targets for treating cognitive dysfunction in schizophrenia.Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors.Reduction of [11C](+)3-MPB binding in brain of chronic fatigue syndrome with serum autoantibody against muscarinic cholinergic receptor.G protein-coupled receptors in major psychiatric disorders.Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor.Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's DiseaseThe search for novel antipsychotics: pharmacological and molecular targets.Cholinergic circuits and signaling in the pathophysiology of schizophreniaChanges in BQCA Allosteric Modulation of [(3)H]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations.Target identification for CNS diseases by transcriptional profiling.The muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtypeAllosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.Intact attentional processing but abnormal responding in M1 muscarinic receptor-deficient mice using an automated touchscreen method.Potential action of betel alkaloids on positive and negative symptoms of schizophrenia: a review.[11C]AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors.Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors.Discovery of potential antipsychotic agents possessing pro-cognitive properties.Problems and solutions to filling the drying drug pipeline for psychiatric disorders: a report from the inaugural 2012 CINP Think Tank.Cholinergic muscarinic receptors: new opportunities to treat psychiatric disorders.Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus.Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia.Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M1 PAM VU6004256.Positive Allosteric Modulation of the Muscarinic M1 Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior.
P2860
Q24645678-8E5196B9-6DB7-457A-AA03-01C55A19746DQ24652668-BF1E4CF2-DC1D-439A-9609-BCC1E4F5A536Q28301970-F52E5FB0-CBB9-4088-8616-88AF797E40BBQ30388923-B3FAD06F-5E2A-4F4E-8837-C50C7DD9817CQ30421323-F1979EBC-6042-46AA-94FD-01BCF82AF45EQ30427199-9E70BC78-2E3A-4596-A00A-C6F933E797A3Q30444290-2EEC40C3-99ED-4556-8ED1-CD7DC9934577Q30457634-F92D72DC-4F2E-437B-A93D-51E2F24B747CQ30491310-05CF4435-B3E4-4158-9134-388466480E76Q33999521-E44114F2-86CA-4596-A6F9-FFA6BF0308CFQ34274859-F5690AFF-B72A-4C98-9CD8-BF9A059A1231Q34338202-0027C883-E364-46FB-BE0E-0028318AB6B8Q34419652-6FE8A9F9-43CF-4F8B-9DC1-058A9D15511BQ34512441-CD826956-D09C-400C-9FD3-23959FF6D21DQ34578414-3B5533B2-B36C-4D5F-994B-9981546A40F3Q34590400-D6156C86-2E13-4ECC-8AC5-2CC80C70DCF7Q34672123-A8CB8475-5739-4A18-BBEB-AEDE69BAAE31Q35789730-1F77A2CF-570F-4507-8D23-0101C50B635BQ35976379-F16E3F4D-6600-48B8-9918-945C8B4C3AFCQ36756379-AE14658D-9E15-4C82-86B2-CB0D053598E2Q36799047-3A456D23-7954-47CF-8A9B-52DBD9EFA3FCQ37175279-B587A2B9-E50E-4DF9-B006-D1B73D1938DCQ37309784-44DD964E-0463-487D-93A6-3C6713242BEBQ37360436-F7FE9C1C-A1DB-4F89-A9AE-F3998EFB3D48Q37506679-C22AA835-11F1-44F2-8417-DD1E76012796Q37920918-B989DFBA-96AD-499C-9C18-920AE5EE174EQ39774300-ED2573E7-C33C-4CF2-BBFE-D9772B29CD0EQ41846364-6D5C0EC8-58C4-4EAC-A0E4-13ED612B3A5FQ42803307-1CED32DA-7CD0-4301-BD6F-C2188C8C033DQ43450643-69B649AC-EF6C-4BED-B4C2-A78CD1368FD2Q44141796-9C0351FF-D9A4-44F7-A691-4CBBAE0EEF6FQ46640346-7C873CBE-AA8B-438A-969C-B594EF2FEA32Q46720641-C86990AB-1350-4BF6-AC8D-E49799D7B135Q47393629-79416379-27C6-4193-9BB9-3E1E3752D687Q48354605-1061D01B-A349-496A-8763-F60E9F76DD22
P2860
Muscarinic receptors as a target for drugs treating schizophrenia.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Muscarinic receptors as a target for drugs treating schizophrenia.
@ast
Muscarinic receptors as a target for drugs treating schizophrenia.
@en
type
label
Muscarinic receptors as a target for drugs treating schizophrenia.
@ast
Muscarinic receptors as a target for drugs treating schizophrenia.
@en
prefLabel
Muscarinic receptors as a target for drugs treating schizophrenia.
@ast
Muscarinic receptors as a target for drugs treating schizophrenia.
@en
P2093
P356
P1476
Muscarinic receptors as a target for drugs treating schizophrenia.
@en
P2093
Christian Felder
David McKinzie
Frank P Bymaster
Saeed Ahmed
P304
P356
10.2174/1568007024606249
P577
2002-04-01T00:00:00Z